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Additionally, recent work from a different cohort treated during acute infection showed 55 that HIV-specific T cell responses could reduce viral load (VL), and limit reservoir 56 seeding, when antiretroviral therapy (ART) was initiated at peak viraemia (8) . 57 T cell activation -a mediator of disease progression and non-AIDS co-morbidities (9-12) 58 -has also been shown in cross-sectional studies to be related to HIV reservoir size (7, 13-59 age of 36 (IQR 28-41) years at the time of ART start. They commenced ART a median of 88 29 (IQR 14-46) days following a confirmed HIV diagnosis and a median of 49 (IQR 33-89 90) days following estimated seroconversion. Different methods for diagnosing PHI 90 (Table 1) were used; 26 participants (41%) were P24 antigen positive without detectable 91 antibodies, consistent with Fiebig stages I or II at the time of diagnosis. 92
The participants had a high median baseline VL (5.5 log10 copies/ml; IQR 4.6-6.5), which 93 declined on ART (Fig. 1A) . 60/63 (95%) were virologically suppressed (<50 copies/ml) 94 after one year of ART (the frequency of viral load sampling and time to suppression is 95
shown in Supplementary Fig. 1 ). The three individuals who had not achieved VL<50 96 copies/ml by one year had estimated VLs (average of those either side of the 1 year time-97 point) of 40, 76 and 190 copies/ml, and achieved undetectability shortly after. The 98 dynamics of CD4 and CD8 count, as well as CD4 to CD8 ratio following ART initiation 99 are shown in Fig. 1B-D . 100
There was a relationship between the first measured (or 'baseline') pVL and the method 101 used to diagnose PHI (Fig. 1E ). Baseline VL was higher when measured closer to 102 estimated seroconversion (rs=-0.58, p=5.0x10 -7 ), suggesting that viral load is of limited 103 utility as a predictive variable in PHI compared with chronic HIV infection, as a stable 104 'set point ' has not yet been reached. 105
Quantitation of total HIV DNA (copies per 10 6 CD4 T cells) is used here as the surrogate 108 measure of reservoir size on ART. Other measures (e.g. integrated HIV DNA, cell-109 associated RNA, quantitative viral outgrowth) were not used for this analysis due to the 110 high numbers of predictive variables being tested. Of note, the term "reservoir" is only 111 used for HIV DNA measurements on suppressive ART as pre-ART DNA measurements 112 will capture cells with active viral replication. Compared with pre-ART levels, HIV DNA 113 decreased a mean of 0.9 log10 copies following one year of therapy ( Fig. 2A ; p=2.2x10 ART initiation, which is, in turn, the main predictor of HIV reservoir size on ART. 148
149

CD8 T cell activation and memory expansion are the key determinants of HIV DNA levels
To more formally assess the strength and independence of these relationships, regression 151 models were fitted to the data. Correlative analyses reinforced the role for baseline total 152 HIV DNA as the key predictor of reservoir size at one year. For this reason, we 153 concentrated on models to assess which variables were most highly related with baseline 154 total HIV DNA (Fig. 4A) . 155
The dataset poses several challenges in the fitting of multivariable regression models, 156 especially as 8.4% of observations are missing ( Supplementary Fig. 3 ) due to unavailable 157 samples, poor sample viability or low cell count. The large number of parameters 158 measured relative to observations, as well as the strong correlations between many of 159 these variables, was also problematic. To ensure the robustness of any conclusions, two 160 different models (boosted regression tree (BRT) and least absolute shrinkage and 161 selection operator (LASSO)) with different approaches to complex data were fitted and 162 their outputs compared. 163
BRT is a machine learning approach that builds a series of regression trees, with each 164 subsequent tree iteratively aiming to improve the previous fit by focusing on data poorly 165 modelled by the existing set of trees. This approach is able to handle missing data, does 166 not make prior assumptions about the effect of potential predictor variables and can 167 handle high-dimensional interactions (33). A BRT model was fitted with baseline total 168 HIV DNA as the outcome, and all other baseline variables as predictors. The relative 169 importance of each predictor variable included in this BRT model is shown in Fig. 4B . 170
The relative influence of each variable is estimated based on the number of times that 171 variable is selected for splitting and the improvement to the model as a result of that split 172 averaged across all trees; a higher number indicates a greater effect of the variable. Wedefined influential predictors as those with a relative influence value greater than 100 174 divided by the total number of variables (indicated by the dashed line). The figure shows 175 that 10 of the 62 predictors had a consistent influence in predicting baseline reservoir 176 size. Notably, CD8 memory subsets (the proportion of EM and naïve cells), as well as 177 CD8 CD38 expression were the variables with the highest relative influence. 178 LASSO is a multivariable regression designed to cope with multi-collinearity and large 179 numbers of predictors by adding a penalty to the coefficient of each term (with the ability 180 to penalise coefficients to zero) thus performing variable selection. Missing values were 181 imputed using a random forest based method. Linear LASSO models were fitted to the 182 data ( (Table 2 ; Supplementary Fig. 4 shows the corresponding BRT models and 199
Supplementary Table 1 One of the key findings of this analysis is that the HIV DNA level prior to ART initiation 238 was the most influential predictor of subsequent reservoir size. Several other studies have 239
shown a relationship between pre-therapy HIV DNA levels and those once virologically 240 suppressed on ART (16, 36, 37). These findings also support previous research 241 suggesting that set point HIV DNA levels in untreated individuals are reached shortly 242 after peak VL (38), and extend it to show that this is true even if ART is started early. 243
Higher levels of initial T cell activation were associated with increased reservoir size. 244 This is consistent with the SPARTAC study where CD38 expression at baseline was 245 significantly associated with total HIV DNA at that time (7). It is possible that this is 246 driven by higher initial viral burden; it could also reflect poorer CD8 effector function 247
suggesting that activation and dysfunction may already be coupled during PHI. Total HIV DNA quantification 389 HIV DNA was quantified relative to cell number using qPCR as previously described 390 (50). In brief, cryopreserved PBMCs were thawed (as above) and CD4 T cells were 391 isolated by negative selection using the EasySep Human CD4 Enrichment Kit (Stemcell 392 Technologies) before DNA extraction with the QiaAMP Blood Mini Kit (Qiagen). Cellcopy number was initially quantified using an albumin qPCR. 25,000 cell equivalents 394 (and no less than 10,000 cell equivalents) of DNA was then used in a total HIV DNA 395 qPCR, performed in triplicate. The mean number of copies of DNA was normalised to 396 cell number and expressed as copies/10 6 CD4 T cells. 397
HLA-typing 398
HLA typing was performed to intermediate resolution using PCR with sequence specific 399
primers (PCR-SSP). 400
Statistics 401
Analyses were performed using R (v3.2.2 or v3.4.3) and GraphPad Prism (v7.0b). Except 402 where otherwise specified, p-values <0.05 were considered statistically significant. 403
Simple comparisons were performed using parametric or non-parametric tests as 404 appropriate and are described alongside the results. 405
Corrgrams were generated using the package corrplot (v0.84). Where some data were 406 missing, pairwise complete observations were used to calculate the correlation 407
coefficients. 408
Boosted regression tree models were fitted with a Gaussian outcome using the package 409 gbm3 (v2.2). Models were fitted with an interaction depth of 5 with a minimum of 5 410 observations in a terminal node. The shrinkage parameter was adjusted between 0.0001 -411 0.001 to aim for optimal number of trees to fall in the range of 3000-10000. The optimal 412 number of trees was determined using 10 fold cross-validation, with the number of treesthat minimised cross-validation error chosen. Results presented are summarised outcomes 414 of 100 models. 415 LASSO models (51) were fitted using the R package glmnet (v2.0-16) (52). Gaussian 416 regression models were fitted with an additive linear model (no interactions). The tuning 417 parameter λ was determined using 10-fold cross-validation, with the λ value used being 418 that which minimised cross-validation error plus one standard error. Where data were 419 imputed this was performed using the package MissForest (53), which employs a random 420 forest based method for multiple imputation and has been shown to be superior to other 421 multiple imputation methods in biological datasets with comparable levels of missingness 422 (53, 54). • Negative test within 6 months of positive test 30 (48%)
• Recent incidence testing algorithm 6 (9.5%)
Mode of acquisition • MSM 56 (89%)
• MSW 1 (1.5%)
• Unknown/unrecorded 6 (9.5%) Initial ART regimen
• Unknown/unrecorded 3 (4.8%) Backbone
• tenofovir containing 55 (87%)
• abacavir containing 5 (7.9%) Additional agent(s)
• protease inhibitor 36 (57%)
• NNRTI 11 (17%)
• integrase inhibitor 12 (19%)
• protease inhibitor + integrase inhibitor 1 (1.5%) 
